Image source: Shutterstock
Highlights
Vitasora Health secures AUD 11 million in placement backed by institutional and long-term shareholders.
Share price falls 23% to AUD 0.03 following discounted equity raise at 16.2% below recent VWAP.
Funds to support growth and operations through to expected cash flow breakeven in H2 FY2026.
Shares of Vitasora Health Limited (ASX: VHL) declined sharply by 23% to AUD 0.03 in morning trade on Wednesday following the announcement of a capital raise totalling AUD 11 million. The raise was completed through a placement to sophisticated, professional, and institutional investors, with backing from both existing and new shareholders.
Despite the successful fundraising effort, the company’s share price declined, reflecting the impact of a 16.2% discount offered to the five-day volume-weighted average price (VWAP) of AUD 0.0358 per share. The discounted offer saw the issue of approximately 350 million fully paid ordinary shares priced at AUD 0.03 per share.
Placement Overview and Investor Participation
The placement, according to Vitasora, received firm commitments and was oversubscribed, underlining continued support for the company’s U.S.-focused connected care strategy. A key institutional investor contributed USD 4.5 million (approximately AUD 6.75 million), making up a significant portion of the total funds raised.
In addition, the company’s CEO and Chairman have committed to participate in the raise for a total of AUD 500,000, subject to shareholder approval. Of the total placement, 194 million shares were issued under ASX Listing Rule 7.1 and 156 million shares under ASX Listing Rule 7.1A.
Funding Allocation and Strategic Use
Proceeds from the capital raise will be directed toward supporting working capital and the company’s growth initiatives, with key focus areas including:
-
Expansion of clinical operations and client program delivery
-
Enhancements to the AI-driven technology platform
-
System integration and client account management
-
Business development, sales, and marketing initiatives
-
Compliance and regulatory costs
The company expects the additional funding will allow it to reach cash flow breakeven by H2 FY2026, positioning it for sustained commercial expansion.
Execution Track Record and Market Positioning
Vitasora highlighted that investor interest was driven by consistent operational execution and recent developments, particularly the on-time delivery of the TPAC agreement, which has since expanded into a value-based care arrangement. The company also reported broader client scope expansion and growing momentum across its sales pipeline.
Formerly known as Respiri Limited, Vitasora has rebranded to reflect its focus on AI-powered Connected Care solutions in the U.S. healthcare market.






Please wait processing your request...